| Similar Articles |
|---|
 |
The Motley Fool
June 4, 2007
Brian Lawler |
Is AtheroGenics Grasping at Straws? The pharmaceutical announces the path forward for its lead drug. Investors, take note.   |
The Motley Fool
April 24, 2007
Brian Lawler |
AtheroGenics Loses a Partner The specialty drug maker's drug-development partner bails. Waiting around for years on more clinical trial results for a drug with such unproven efficacy is not something that is a recipe for success with specialty pharma stock investing. |
The Motley Fool
March 28, 2007
Brian Lawler |
AtheroGenics Splices the Data Shares of AtheroGenics will continue to be volatile in the next couple of months as investors await the probable discontinuation of the company's partnership with AstraZeneca. |
The Motley Fool
February 26, 2007
Brian Lawler |
Waiting on AtheroGenics The results might be positive for this pharma, but don't bet on it. Investors, take note. |
The Motley Fool
March 20, 2007
Brian Lawler |
Heart Attack at AtheroGenics Shares of AtheroGenics drop after negative phase 3 trial results. |
The Motley Fool
October 24, 2006
Brian Lawler |
Playing the AtheroGenics Waiting Game The results of phase 3 trials for the company's atherosclerosis drug will determine AtheroGenics' future. Investors, take note. |
The Motley Fool
August 30, 2005
Charly Travers |
A Drug to Make Hearts Happy? Atherogenics has a potential blockbuster in a drug that could reverse the clogging of arteries. Investors, take note. |
BusinessWeek
September 5, 2005
Gene G. Marcial |
AtheroGenics May Be A Buyout AtheroGenics is one of the more attractive acquisition candidates of Merck or Pfizer. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
July 8, 2008
Brian Lawler |
Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards. |
The Motley Fool
January 27, 2004
David Nierengarten |
Pfizer's Next Target? Esperion, swallowed by Pfizer last year, shares many similarities with Atherogenics. Investors in the latter, however, should not count on being acquired any time soon by a big pharmaceutical company. |
The Motley Fool
February 1, 2008
Brian Lawler |
AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs. |
Nursing Management
January 2012
Lawrence et al. |
Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support. |
The Motley Fool
January 11, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Semiconductor Manufacturing International... Herbalife... New York & Company... Atherogenics... Hot Topic... |
The Motley Fool
November 24, 2010
Brian Orelli |
Profit From the United States of Diabetes Half the country could have an early form by 2020. |
Pharmaceutical Executive
October 1, 2006
Rob Scott |
Thoughtleader: Life After Lipitor A conversation with a former Pfizer executive who "launched the world's best-selling drug." |
AskMen.com
Alex Santoso |
What You Should Know About Diabetes Not many men understand what diabetes is, why it's very bad for them (it is one of the leading causes of impotence), what they can do to avoid getting it or how to treat it. |
Pharmaceutical Executive
October 1, 2005 |
Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions. |
AskMen.com
April 29, 2001
Joshua Levine |
Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease... |
The Motley Fool
February 12, 2007
Bill Barker |
How to Win CNBC's Million-Dollar Challenge You can win -- but not with a sane investing strategy. AtheroGenics is a stock tailor-made for this game. |
American Family Physician
October 15, 2003
Gavin et al. |
Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes By increasing patient awareness of the link between diabetes and heart disease, family physicians can encourage patients to take medications (including aspirin), stop smoking, lower blood pressure, and lower cholesterol and blood glucose levels. |
American Family Physician
November 1, 2000 |
Diabetes: How Do I Know if I Have it? Diabetes is a disease that occurs when your body doesn't make enough of a hormone called insulin, or if your body doesn't use insulin the right way. If left untreated, it may result in blindness, heart attacks, strokes, kidney failure and amputations... |
American Family Physician
October 15, 2003 |
Diabetes and Heart Disease I have diabetes -- why should I worry about heart disease?... What are the ABCs of diabetes?... Where can I learn more about diabetes and heart disease?... What can I do to reduce my risk for heart disease? |
The Motley Fool
December 28, 2005
Stephen D. Simpson |
AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either. |
American Family Physician
April 15, 2004 |
Taking Steps to Prevent Type 2 Diabetes Information on type 2 diabetes: detection, who is at risk, and prevention. |
Managed Care
February 2001
Michael S. Victoroff |
Helping Patients Make Informed Decisions Now Harder Thanks to Range of Treatment The duty of informed consent necessitates that physicians discuss with their patients the realistic expectations and risks associated with treatment. When no protocol shows a distinct advantage, there is no duty to inform, which creates an ethical problem for physicians... |
Managed Care
June 2007 |
Seventy Percent Surge In Diabetes Spending Spending on endocrine and diabetes therapies could surge nearly 70% in the next two years, according to research. Diabetes treatments were the second leading contributor in total dollars to prescription drug spending growth in 2006. |
The Motley Fool
October 25, 2005
Tim Beyers |
Who's Buying Now? Data management, heart drugs, and medicine for tots top this week's list of insider buys: Acxiom... AtheroGenics... ITT Educational Services... Natus Medical... Tessco Technologies... etc. |
Chemistry World
December 20, 2013
Patrick Walter |
AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture. |
